Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02. Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.

On December22, 2016, Novelion Therapeutics Inc. (the
Company) granted stock options (the Stock Option
Awards) and performance-based restricted stock units
(RSUs) to its Chief Executive Officer, Mary Szela, its
Chief Financial and Administrative Officer, Gregory Perry, and
other executive officers. The grants were made under the Companys
2016 Equity Incentive Plan and were approved by the Compensation
Committee of the Board of Directors. The awards to Ms.Szela and
Mr.Perry were as follows:

Vesting of the RSUs is subject to achievement of regulatory and
development milestones with respect to MYALEPT (metreleptin) and
specified revenues from JUXTAPID (lomitapide) in Japan. One-third
of the RSUs awarded are subject to vesting upon achievement of
the performance targets, with the remaining two-thirds of the
RSUs subject to vesting in substantially equal annual
installments on the second and third anniversaries of the grant
date conditional upon achievement of the performance targets.

The Stock Option Awards are subject to time-based vesting in
three substantially equal installments on December22, 2017,
December22, 2018 and December22, 2019, respectively.

Item 8.01. Other Events.

On December22, 2016, the Company issued a press release
announcing that its subsidiary Aegerion Pharmaceuticals,Inc.
submitted a marketing authorization application to the European
Medicines Agency on December21, 2016, seeking approval for
metreleptin as replacement therapy to treat complications of
leptin deficiency in patients with congenital or acquired
generalized lipodystrophy and in a subset of patients with
partial lipodystrophy. The press release is attached as
Exhibit99.1 to this Current Report on Form8-K and is incorporated
by reference into this Item 8.01.

Item 9.01. Financial Statements and
Exhibits.

(d)Exhibits.